Michael Kaufman
2019
In 2019, Michael Kaufman earned a total compensation of $862.4K as Chief Manufacturing Officer at Mersana Therapeutics, a 9% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $169,770 |
|---|---|
| Option Awards | $139,764 |
| Salary | $385,840 |
| Stock Awards | $160,000 |
| Other | $7,000 |
| Total | $862,374 |
Kaufman received $385.8K in salary, accounting for 45% of the total pay in 2019.
Kaufman also received $169.8K in non-equity incentive plan, $139.8K in option awards, $160K in stock awards and $7K in other compensation.
Rankings
In 2019, Michael Kaufman's compensation ranked 9,924th out of 13,971 executives tracked by ExecPay. In other words, Kaufman earned more than 29.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,924 out of 13,971 | 29th |
Division Manufacturing | 4,009 out of 5,701 | 30th |
Major group Chemicals And Allied Products | 1,524 out of 2,200 | 31st |
Industry group Drugs | 1,304 out of 1,886 | 31st |
Industry Pharmaceutical Preparations | 969 out of 1,398 | 31st |
Source: SEC filing on April 27, 2021.
Kaufman's colleagues
We found four more compensation records of executives who worked with Michael Kaufman at Mersana Therapeutics in 2019.
2019
Anna Protopapas
Mersana Therapeutics
Chief Executive Officer
2019
Dirk Huebner
Mersana Therapeutics
Chief Medical Officer
2019
Brian DeSchuytner
Mersana Therapeutics
Senior Vice President, Finance & Product Strategy
2019
Timothy Lowinger
Mersana Therapeutics
Chief Science and Technology Officer
News
Mersana Therapeutics CEO Anna Protopapas' 2021 pay jumps 226% to $8.3M
April 29, 2022
Mersana Therapeutics Chief Medical Officer Arvin Yang receives $4.5M in 2020
April 27, 2021
Mersana Therapeutics CEO Anna Protopapas' 2019 pay falls 33% to $1.7M
April 20, 2020
Mersana Therapeutics CEO Anna Protopapas' 2018 pay jumps 184% to $2.6M
April 23, 2019